A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism
- PMID: 17932107
- PMCID: PMC2234586
- DOI: 10.1210/me.2007-0221
A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism
Abstract
By proposing TSH as a key negative regulator of bone turnover, recent studies in TSH receptor (TSHR) null mice challenged the established view that skeletal responses to disruption of the hypothalamic-pituitary-thyroid axis result from altered thyroid hormone (T(3)) action in bone. Importantly, this hypothesis does not explain the increased risk of osteoporosis in Graves' disease patients, in which circulating TSHR-stimulating antibodies are pathognomonic. To determine the relative importance of T(3) and TSH in bone, we compared the skeletal phenotypes of two mouse models of congenital hypothyroidism in which the normal reciprocal relationship between thyroid hormones and TSH was intact or disrupted. Pax8 null (Pax8(-/-)) mice have a 1900-fold increase in TSH and a normal TSHR, whereas hyt/hyt mice have a 2300-fold elevation of TSH but a nonfunctional TSHR. We reasoned these mice must display opposing skeletal phenotypes if TSH has a major role in bone, whereas they would be similar if thyroid hormone actions predominate. Pax8(-/-) and hyt/hyt mice both displayed delayed ossification, reduced cortical bone, a trabecular bone remodeling defect, and reduced bone mineralization, thus indicating that the skeletal abnormalities of congenital hypothyroidism are independent of TSH. Treatment of primary osteoblasts and osteoclasts with TSH or a TSHR-stimulating antibody failed to induce a cAMP response. Furthermore, TSH did not affect the differentiation or function of osteoblasts or osteoclasts in vitro. These data indicate the hypothalamic-pituitary-thyroid axis regulates skeletal development via the actions of T(3).
Figures
Similar articles
-
Excess TSH causes abnormal skeletal development in young mice with hypothyroidism via suppressive effects on the growth plate.Am J Physiol Endocrinol Metab. 2013 Sep 1;305(5):E660-6. doi: 10.1152/ajpendo.00067.2013. Epub 2013 Jul 23. Am J Physiol Endocrinol Metab. 2013. PMID: 23880310
-
Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland.Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15462-7. doi: 10.1073/pnas.242328999. Epub 2002 Nov 13. Proc Natl Acad Sci U S A. 2002. PMID: 12432093 Free PMC article.
-
The site of the molecular defect in the thyroid gland of the hyt/hyt mouse: abnormalities in the TSH receptor-G protein complex.Thyroid. 1991 Summer;1(3):257-66. doi: 10.1089/thy.1991.1.257. Thyroid. 1991. PMID: 1668617
-
Effects of thyroid status on bone metabolism: a primary role for thyroid stimulating hormone or thyroid hormone?Minerva Endocrinol. 2005 Dec;30(4):237-46. Minerva Endocrinol. 2005. PMID: 16319811 Review.
-
Critical role of the hypothalamic-pituitary-thyroid axis in bone.Bone. 2008 Sep;43(3):418-26. doi: 10.1016/j.bone.2008.05.007. Epub 2008 May 16. Bone. 2008. PMID: 18585995 Review.
Cited by
-
Thyroid disease in pregnancy in 2011: Thyroid function--effects on mother and baby unraveled.Nat Rev Endocrinol. 2011 Dec 6;8(2):69-70. doi: 10.1038/nrendo.2011.217. Nat Rev Endocrinol. 2011. PMID: 22143186 Review.
-
TSH suppressive therapy and bone.Endocr Connect. 2020 Jul;9(7):R158-R172. doi: 10.1530/EC-20-0167. Endocr Connect. 2020. PMID: 32567550 Free PMC article. Review.
-
Human TSH receptor ligands as pharmacological probes with potential clinical application.Expert Rev Endocrinol Metab. 2009 Nov 1;4(6):669. doi: 10.1586/eem.09.36. Expert Rev Endocrinol Metab. 2009. PMID: 20161662 Free PMC article.
-
Insulin-like growth factor binding protein-6 interacts with the thyroid hormone receptor α1 and modulates the thyroid hormone-response in osteoblastic differentiation.Mol Cell Biochem. 2012 Feb;361(1-2):197-208. doi: 10.1007/s11010-011-1104-y. Epub 2011 Oct 14. Mol Cell Biochem. 2012. PMID: 21997736
-
Bone circuitry and interorgan skeletal crosstalk.Elife. 2023 Jan 19;12:e83142. doi: 10.7554/eLife.83142. Elife. 2023. PMID: 36656634 Free PMC article.
References
-
- Kanis JA, Johnell O 2005 Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238 - PubMed
-
- Ray NF, Chan JK, Thamer M, Melton 3rd LJ 1997 Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35 - PubMed
-
- Mosekilde L, Eriksen EF, Charles P 1990 Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 19:35–63 - PubMed
-
- Vestergaard P, Mosekilde L 2002 Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12:411–419 - PubMed
-
- Bauer DC, Ettinger B, Nevitt MC, Stone LS 2001 Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561–568 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
